Head of Clinical Physiology for Richmond Pharmacology, Bablu Singh attended the British Cardiovascular Society (BCS) conference as a member of Faculty this month.

Future-proofing Cardiology for the next 10 years

The British Cardiovascular Society (BCS) 2023 conference returned to the Manchester Central conference centre on the 5th June. For two days, Doctors, Physiologists, Researchers and other clinicians came together to explore workforce capabilities, resilience, sustainability and multi-disciplinary working.

Upskilling the workforce

Bablu Singh, Head of Clinical Physiology at Richmond Pharmacology joined the conference as a member of Faculty, providing practical training in Adult Transthoracic Echocardiology to clinical staff attending the conference. Bablu said he was 'honoured' to have been able to support such a prestigious body that plays a pivotal role in the delivery of cardiovascular health across the UK.

London's Regional Representative

Alongside playing a key role in upskilling the workforce, Bablu was also nominated as the Regional Representative for London at the British Society of Echocardiography (BSE).The Regional Representatives are a point of contact between members and the BSE. They communicate concerns and queries from the workplace into the committees and the Advisory Council and disseminate information back into workplaces from the BSE. This can be any topic from ergonomics and staff well-being to workforce issues, etc.

The reps are also on hand to help members link up with BSE mentors and trainers within their region and organise education meetings.

For more information about Richmond Pharmacology’s expertisein Cardiology, click here.

Latest news

Patient safety is not an afterthought. Explore our new infographic!

September 17, 2025
Patient safety is not an afterthought; it is the foundation of every clinical trial.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event